What Is Selank? A Complete Scientific Guide

Selank is a synthetic peptide developed primarily for research into anxiety, stress and cognitive function.

It is commonly described online as both an:

• Anxiolytic peptide

• Nootropic peptide

An anxiolytic is a substance investigated for reducing anxiety, while a nootropic is a substance claimed to influence cognitive processes such as memory, attention or learning.

Selank is unusual because it was not designed to stimulate a single clearly identified receptor.

Instead, experimental research suggests that it may influence several interconnected systems involving:

• GABA signalling

• Enkephalin metabolism

• Gene expression

• Neurotrophic factors

• Immune signalling

• Stress responses

Small clinical studies conducted mainly in Russia have reported reductions in anxiety symptoms. However, the overall human evidence remains limited by:

• Small participant numbers

• Short study durations

• Limited independent replication

• A concentration of research from a small number of institutions

• Limited publication in large international clinical journals

Selank has not undergone the type of extensive multinational clinical-development programme expected for a widely approved psychiatric medicine.

It should therefore not be presented as an established replacement for evidence-based treatments for anxiety disorders.

This guide examines what Selank is, how it was developed, what mechanisms have been proposed, what human research has reported and where substantial uncertainty remains.

Selank quick facts

Selank is structurally based on a short fragment associated with tuftsin, with three additional amino acids added to improve metabolic stability.

What is Selank?

Selank is a synthetic peptide composed of seven amino acids.

Its amino acid sequence is:

Thr-Lys-Pro-Arg-Pro-Gly-Pro

This is commonly abbreviated to:

TKPRPGP

The first four amino acids correspond to a short sequence associated with tuftsin:

Thr-Lys-Pro-Arg

Three additional amino acids were added:

Pro-Gly-Pro

These additions were intended to increase the molecule’s resistance to enzymatic breakdown and extend its biological activity.

Selank is therefore best described as a synthetic tuftsin-related peptide, rather than as a naturally circulating human hormone.

What is tuftsin?

Tuftsin is a naturally occurring tetrapeptide with the sequence:

Thr-Lys-Pro-Arg

It is derived from part of the heavy chain of human immunoglobulin G.

Tuftsin has been investigated primarily for its effects on immune-cell activity, including interactions involving:

• Phagocytosis

• Macrophages

• Neutrophils

• Immune signalling

Selank retains the tuftsin-related sequence but was developed for a different research focus, particularly anxiety and nervous-system function.

The biological effects of Selank should not automatically be assumed to be identical to those of tuftsin.

How was Selank developed?

Selank was developed by researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences.

The objective was to create a peptide with potential anti-anxiety effects that might avoid some limitations associated with traditional sedating anxiolytic drugs.

Researchers were particularly interested in whether a peptide-based compound could influence anxiety without producing substantial:

• Sedation

• Muscle relaxation

• Memory impairment

• Physical dependence

Early laboratory and clinical studies reported encouraging findings, but these results have not yet been confirmed through large international phase III trials.

Is Selank a nootropic?

Selank is frequently classified as a nootropic because animal experiments have reported effects on:

• Learning

• Memory

• Attention

• Exploratory behaviour

One rodent study found that Selank improved learning performance primarily in animals that initially demonstrated poorer learning ability.

This does not establish that Selank improves cognition in healthy humans.

Evidence from animal learning tests cannot automatically be translated into improvements in:

• Human intelligence

• Academic performance

• Workplace productivity

• Long-term memory

• Attention-deficit disorders

The term nootropic should therefore be used cautiously.

How does Selank work?

Selank does not have a single conclusively identified primary receptor.

Instead, its proposed actions involve several biological systems.

These may include:

• GABAergic signalling

• Enkephalin metabolism

• Neurotrophic-factor expression

• Neurotransmitter-related gene activity

• Immune and cytokine signalling

• Functional connectivity between brain regions

Most of these mechanisms remain experimental.

A biological pathway that appears to change after treatment does not necessarily prove that it is responsible for a clinical effect.

Selank and GABA

Gamma-aminobutyric acid, or GABA, is the principal inhibitory neurotransmitter in the human brain.

GABA helps reduce excessive neuronal activity and contributes to:

• Calmness

• Sleep regulation

• Muscle control

• Stress responses

• Seizure protection

Benzodiazepines such as diazepam reduce anxiety largely by enhancing signalling at GABA-A receptors.

Experimental research suggests Selank may alter the expression of genes involved in GABAergic neurotransmission.

However, Selank is not established as a conventional direct GABA-A receptor agonist or benzodiazepine-like allosteric modulator.

Its interaction with the GABA system may be indirect and considerably more complex.

Gene-expression studies have reported changes involving neurotransmission-related pathways following Selank exposure, but the clinical meaning of these changes remains uncertain.

Is Selank a benzodiazepine?

No.

Selank is chemically and pharmacologically distinct from benzodiazepines.

Benzodiazepines are small-molecule medicines that bind to a specific site on GABA-A receptors and amplify inhibitory GABA signalling.

Selank is a seven-amino-acid peptide and does not share the same chemical structure.

Small studies have compared Selank with benzodiazepine treatment, but a clinical comparison does not mean the substances work identically.

Selank and diazepam

Animal research has examined Selank alongside diazepam.

One study investigated how Selank, diazepam and their combination influenced anxiety-related behaviour under experimental stress conditions.

The findings suggested that their effects may interact, but the work was conducted in animal models and cannot determine the safety or effectiveness of combining them in humans.

Clinical research has also explored Selank alongside benzodiazepine therapy in anxiety-spectrum disorders.

These studies remain relatively small and do not provide sufficient evidence for unsupervised combination use.

Selank and enkephalins

Enkephalins are naturally occurring opioid peptides involved in:

• Pain perception

• Stress responses

• Mood

• Reward signalling

• Emotional regulation

Enkephalins are rapidly broken down by specialised enzymes known as enkephalinases.

Laboratory studies suggest that Selank can inhibit certain enzymes involved in enkephalin degradation.

This could theoretically extend the activity of endogenous enkephalins.

Animal research has also reported that Selank increased the measured half-life of leu-enkephalin in some mouse strains.

Interestingly, the response differed between strains, highlighting how biological effects may depend on genetic or behavioural phenotype.

It has not been conclusively demonstrated that enkephalin inhibition is the primary mechanism behind Selank’s reported effects in humans.

Selank and gene expression

Several laboratory studies have examined changes in gene expression following Selank administration.

Reported effects have involved genes associated with:

• Neurotransmission

• GABA receptors

• Immune responses

• Synaptic function

• Cellular signalling

• Neuroplasticity

Gene expression describes whether particular genes are being used to produce RNA and proteins.

A measurable gene-expression change does not automatically mean that:

• A person will experience a clinical benefit.

• The effect will persist.

• The change is beneficial in every context.

• The same response occurs in humans.

These findings are mechanistically interesting but remain largely exploratory.

Selank and BDNF

Brain-derived neurotrophic factor, commonly known as BDNF, supports:

• Neuronal survival

• Synaptic plasticity

• Learning

• Memory

• Adaptation to stress

Preclinical studies involving Selank have reported possible changes in neurotrophic-factor pathways.

This has contributed to claims that Selank is “neuroprotective.”

However, direct evidence demonstrating that Selank prevents human neurodegenerative disease or clinically meaningful neuronal injury is lacking.

Changes in BDNF-related signalling should not be equated with proven protection from:

• Alzheimer’s disease

• Parkinson’s disease

• Stroke

• Traumatic brain injury

• Age-related cognitive decline

Selank and anxiety research

Anxiety has been the main focus of Selank’s clinical development.

Small studies involving people with generalised anxiety disorder and anxiety-related conditions have reported improvements in symptom measures.

One clinical-biological study involving patients with generalised anxiety disorder and neurasthenia examined anxiety symptoms alongside leu-enkephalin metabolism.

The researchers reported changes during Selank treatment, particularly among patients with generalised anxiety disorder.

Another comparative study reported an anxiolytic effect and suggested that some benefits remained detectable for approximately one week after treatment ended.

These findings are noteworthy, but they do not provide the same evidential strength as several large, independently replicated, placebo-controlled international trials.

What is generalised anxiety disorder?

Generalised anxiety disorder, or GAD, is a recognised mental-health condition characterised by excessive and difficult-to-control worry.

Symptoms may include:

• Persistent anxiety

• Restlessness

• Muscle tension

• Irritability

• Difficulty concentrating

• Sleep disturbance

• Fatigue

Established treatments include:

• Cognitive behavioural therapy

• Selective serotonin reuptake inhibitors

• Serotonin-norepinephrine reuptake inhibitors

• Other clinically supervised medicines

Selank is not an approved UK treatment for generalised anxiety disorder.

How strong is the anxiety evidence?

The existing research provides an early signal that warrants further investigation.

However, major limitations include:

Small trials

Many studies involved relatively few participants.

Small studies are more vulnerable to chance findings and exaggerated effect sizes.

Limited geographical diversity

Most clinical research was performed within Russia or neighbouring scientific networks.

Limited independent replication

A substantial proportion of the literature comes from researchers associated with Selank’s development.

Incomplete reporting

Some studies provide less methodological detail than would be expected from modern international clinical trials.

Limited long-term data

Anxiety disorders are often chronic, but most Selank studies were comparatively short.

The most accurate conclusion is that Selank has preliminary human anxiolytic evidence, not that it is a proven anxiety treatment.

Selank and stress

Animal experiments suggest Selank may alter behavioural and biological responses to stress.

Reported observations have included changes in:

• Anxiety-like behaviour

• Exploratory activity

• Stress adaptation

• Aggressive behaviour

• Neurochemical signalling

These effects have contributed to descriptions of Selank as an “anti-stress peptide.”

This term is not a recognised clinical indication.

Stress is not one single biological process, and reduced anxiety-like behaviour in rodents does not necessarily predict improved resilience in humans.

Selank and cortisol

Online claims frequently state that Selank lowers cortisol.

The available evidence does not establish a predictable or clinically validated cortisol-lowering effect in humans.

Stress-hormone regulation depends on:

• Time of day

• Sleep

• Illness

• Psychological state

• Medication

• Metabolic health

• Sampling conditions

A single cortisol measurement is therefore difficult to interpret.

Selank should not be described as an established treatment for abnormal cortisol levels.

Selank and depression

Preclinical literature sometimes describes Selank as having antidepressant-like effects.

These findings generally come from animal behavioural models.

An animal displaying less immobility or more exploratory behaviour does not directly demonstrate treatment of human major depressive disorder.

There is currently insufficient high-quality evidence to classify Selank as an antidepressant.

Depression may involve significant risks, including self-harm, and should not be self-treated with experimental peptides.

Selank and cognition

Possible cognitive effects have been investigated through:

• Animal learning tests

• Memory tasks

• Brain imaging

• Functional-connectivity studies

A study involving 52 healthy participants examined resting-state brain connectivity after Selank or Semax exposure.

The researchers evaluated networks involving regions such as the amygdala and dorsolateral prefrontal cortex.

Brain-imaging changes do not automatically demonstrate improved cognition or mental-health outcomes.

They show that measurable brain activity or network relationships may have changed under the study conditions.

Selank and memory

Animal studies have reported improvements in certain learning and memory tasks.

The effect may be more pronounced in animals with initially poor learning performance.

There is not yet strong evidence that Selank reliably improves memory in healthy adults.

Claims that it produces:

• Photographic memory

• Major IQ increases

• Immediate learning enhancement

• Protection against dementia

are unsupported.

Selank and focus

Focus is influenced by numerous factors, including:

• Sleep

• Anxiety

• Motivation

• Depression

• Attention disorders

• Medication

• Stress

• Environment

Reducing anxiety could indirectly improve concentration in some people.

That does not establish Selank as a direct attention-enhancing treatment.

It has not been proven to treat attention-deficit hyperactivity disorder.

Selank and brain connectivity

Functional magnetic resonance imaging can measure patterns of correlated activity between brain regions.

Research involving Selank has examined connectivity in networks associated with:

• Anxiety

• Emotional processing

• Executive function

• Working memory

These studies are exploratory.

Functional-connectivity differences are not equivalent to clinical improvement and may be difficult to interpret without replication.

Selank and immune signalling

Because Selank is derived from a tuftsin-related sequence, researchers have examined whether it influences immune function.

A small study in patients with generalised anxiety disorder and neurasthenia reported changes in the balance of certain cytokines after a 14-day course.

Cytokines are signalling proteins used by the immune system.

Changes in cytokine measurements do not establish that Selank:

• Strengthens immunity

• Prevents infection

• Treats autoimmune disease

• Reduces harmful inflammation

• Protects against cancer

Immune effects may be beneficial, neutral or harmful depending on the biological context.

Is Selank an immunomodulator?

Selank has demonstrated immunomodulatory effects in some experimental studies.

An immunomodulator is a substance that changes immune-system activity.

This does not necessarily mean that it “boosts” the immune system.

An excessively activated immune response can contribute to:

• Autoimmune disease

• Allergy

• Chronic inflammation

• Tissue damage

More research is required to determine the clinical significance of Selank’s reported immune effects.

Selank and inflammation

Selank may influence inflammatory signalling through cytokine-related pathways.

However, direct evidence that it treats inflammatory disease is lacking.

It should not be presented as an established treatment for:

• Rheumatoid arthritis

• Inflammatory bowel disease

• Asthma

• Autoimmune disorders

• Chronic inflammatory conditions

Selank and pain

Because Selank may influence enkephalin metabolism, researchers have proposed possible effects on pain signalling.

Human analgesic evidence remains insufficient.

Selank is not an established pain medicine and should not be assumed to reproduce the effects of opioid drugs.

Selank and sleep

Selank is sometimes claimed to improve sleep.

Anxiety reduction could theoretically help a person sleep more easily, but this would be an indirect effect.

Selank is not a conventional sedative and has not been established as a treatment for:

• Insomnia

• Sleep apnoea

• Circadian-rhythm disorders

• Restless legs syndrome

• Parasomnias

Sleep benefits reported online remain largely anecdotal.

Does Selank cause sedation?

Small studies and experimental reports often describe Selank as producing anxiolytic effects without the marked sedation associated with some benzodiazepines.

However, the absence of heavy sedation in small trials does not guarantee that no individual will experience:

• Tiredness

• Dizziness

• Reduced alertness

• Cognitive changes

Controlled safety data remain limited.

Does Selank cause dependence?

There is no strong clinical evidence that Selank produces the same type of physical dependence associated with long-term benzodiazepine use.

However, long-term controlled studies specifically examining:

• Tolerance

• Withdrawal

• Dependence

• Compulsive use

are lacking.

Absence of evidence is not proof that dependence or rebound effects are impossible.

Selank and alcohol withdrawal

Some related peptide research has explored stress and withdrawal models.

However, evidence is insufficient to recommend Selank for alcohol withdrawal.

Alcohol withdrawal can cause:

• Seizures

• Delirium

• Severe autonomic instability

• Death

It requires appropriate medical assessment rather than self-treatment with experimental compounds.

How is Selank studied?

Selank has most commonly been investigated using intranasal administration.

The nasal cavity provides access to a highly vascular surface and is frequently used in research involving compounds intended to influence the central nervous system.

However, intranasal delivery does not guarantee that a peptide reaches the brain in predictable concentrations.

Factors affecting absorption include:

• Formulation

• Molecular stability

• Nasal health

• Spray technique

• Mucus clearance

• Enzymatic degradation

Commercial intranasal products should not be assumed to reproduce the formulations used in clinical studies.

Can Selank cross the blood-brain barrier?

This question remains more complicated than many commercial descriptions suggest.

Potential central effects could occur through:

• Direct transport into the brain

• Nose-to-brain pathways

• Peripheral signalling

• Metabolites

• Neuroimmune interactions

The proportion of a dose reaching specific human brain regions has not been fully characterised.

A central nervous-system effect does not necessarily prove that large quantities of intact Selank cross the blood-brain barrier.

Selank metabolites

Peptides may be broken down into smaller fragments by enzymes in blood and tissues.

Some biological effects attributed to Selank could potentially involve:

• The intact peptide

• Shorter peptide fragments

• Downstream signalling changes

The pharmacological significance of individual metabolites remains incompletely understood.

Selank half-life

Reliable, comprehensive human pharmacokinetic data are limited.

A peptide’s half-life describes how long it takes for its measured concentration to fall by half.

Half-life does not necessarily determine the total duration of an effect.

A short-lived peptide may trigger signalling changes that persist after the original molecule has been degraded.

Claims assigning Selank a precise universal human half-life should therefore be treated cautiously unless supported by validated pharmacokinetic studies.

Human clinical evidence

The human evidence base includes:

• Small anxiety studies

• Comparative studies involving established anxiolytics

• Neurophysiological research

• Functional brain-imaging work

• Immune-marker studies

Several publications report positive findings.

However, the evidence remains much smaller than that supporting established anxiety treatments.

There is insufficient large-scale evidence to determine:

• The optimal clinical population

• Long-term effectiveness

• Relapse rates

• Long-term adverse effects

• Interactions with psychiatric medicines

• Effects during pregnancy

• Effects in adolescents

• Comparative effectiveness against psychotherapy

Regulatory status

Selank is not an authorised medicine in the United Kingdom.

It has not received approval from the UK Medicines and Healthcare products Regulatory Agency for treating:

• Anxiety

• Depression

• Cognitive impairment

• Insomnia

• Stress-related disorders

A product being described as a “research chemical” does not establish:

• Pharmaceutical quality

• Clinical safety

• Legal suitability for human use

• Medical effectiveness

Is Selank approved in Russia?

Selank has been described in published literature as a peptide drug developed and used within Russia.

Regulatory terminology and product status can differ between countries.

Even where a compound has a form of domestic authorisation, this does not mean it has undergone approval by:

• The MHRA

• The European Medicines Agency

• The US Food and Drug Administration

Evidence and legal status must be assessed within the relevant jurisdiction.

WADA status

Selank is not specifically named on the World Anti-Doping Agency’s 2026 Prohibited List.

However, athletes should not interpret the absence of a specific name as a guarantee of acceptability.

The list contains broad categories and may cover substances according to:

• Biological effect

• Chemical similarity

• Regulatory status

• Method of administration

Athletes remain responsible for every substance detected in their samples and should obtain specialist anti-doping guidance before using any experimental compound.

Safety and adverse effects

Published studies generally describe Selank as reasonably well tolerated over short periods.

However, the size and duration of the evidence base are insufficient to establish comprehensive safety.

Potential concerns include:

• Nasal irritation

• Headache

• Dizziness

• Fatigue

• Unexpected mood changes

• Allergic reactions

• Product contamination

• Interactions with other medicines

Rare adverse effects may not appear until thousands of people have been studied.

Selank has not yet accumulated this level of modern safety data.

Psychiatric considerations

Compounds that influence anxiety, mood or neurotransmission may affect individuals differently.

Particular caution is warranted in people with:

• Bipolar disorder

• Psychosis

• Severe depression

• Panic disorder

• Substance-use disorders

• Suicidal thoughts

• Complex psychiatric medication regimens

Changes in mood or behaviour require appropriate clinical evaluation.

Selank and antidepressants

There are insufficient controlled data to establish the safety of combining Selank with:

• SSRIs

• SNRIs

• Tricyclic antidepressants

• Monoamine oxidase inhibitors

• Atypical antidepressants

A lack of documented interaction does not prove that an interaction cannot occur.

Selank and benzodiazepines

Small studies have investigated Selank alongside benzodiazepines.

This does not establish the safety of unsupervised combination use.

Potential issues may include:

• Excessive sedation

• Impaired coordination

• Altered anxiety symptoms

• Difficulty identifying which substance caused an adverse effect

Medication changes should be supervised by an appropriate clinician.

Selank and alcohol

There is insufficient evidence to define the interaction between Selank and alcohol.

Combining psychoactive or experimental compounds with alcohol may produce unpredictable effects on:

• Alertness

• Coordination

• Mood

• Judgement

• Anxiety

Pregnancy and breastfeeding

There is insufficient evidence to establish the safety of Selank during:

• Pregnancy

• Breastfeeding

• Fertility treatment

Peptides that influence neuroendocrine or immune pathways could theoretically affect maternal or fetal biology.

Use in these populations cannot be considered established as safe.

Children and adolescents

The safety and effectiveness of Selank in children and adolescents have not been adequately established through large modern clinical trials.

Developing brains may respond differently from adult brains.

Product-quality concerns

Even where a peptide is chemically well defined, a commercial product may differ from the compound used in published research.

Important quality factors include:

• Correct amino acid sequence

• Peptide purity

• Concentration accuracy

• Sterility

• Endotoxin levels

• Solvent composition

• Degradation

• Storage conditions

A purity percentage alone does not demonstrate sterility or verify that the correct peptide is present.

Analytical testing

Common laboratory methods may include:

High-performance liquid chromatography

HPLC can estimate chemical purity and identify some impurities.

Mass spectrometry

Mass spectrometry can help confirm molecular mass and identity.

Microbiological testing

This assesses contamination by microorganisms.

Endotoxin testing

This measures inflammatory bacterial components that may remain even when living bacteria are absent.

No single test establishes every aspect of product quality.

Common Selank myths

Myth: Selank is natural.

Fact: Selank is a synthetic seven-amino-acid peptide derived from a tuftsin-related sequence.

Myth: Selank works exactly like a benzodiazepine.

Fact: It is chemically distinct, and its mechanism has not been fully defined.

Myth: Selank is clinically proven to cure anxiety.

Fact: Small studies report promising findings, but large independent international trials remain lacking.

Myth: Selank permanently rewires the brain.

Fact: Research has identified signalling and connectivity changes, but permanent beneficial rewiring has not been demonstrated.

Myth: Selank cannot cause side effects.

Fact: Its full long-term safety profile is unknown.

Myth: Selank improves intelligence.

Fact: Animal learning studies do not establish increases in human intelligence.

Myth: Intranasal use guarantees direct brain delivery.

Fact: Intranasal absorption and nose-to-brain transport are variable and formulation dependent.

Myth: A peptide cannot interact with medication.

Fact: Peptides can influence biological pathways and may interact with medicines or medical conditions.

Frequently asked questions

Is Selank a peptide?

Yes. Selank is a synthetic peptide made from seven amino acids.

What is Selank derived from?

It is derived from a sequence related to tuftsin, a naturally occurring immune-associated peptide.

Is Selank naturally produced by humans?

Selank itself is a synthetic analogue. Its first four amino acids correspond to the tuftsin sequence.

What is Selank mainly researched for?

Its primary research areas are anxiety, stress and cognitive function.

Does Selank have a known receptor?

No single primary receptor has been conclusively established.

Does Selank affect GABA?

Experimental evidence suggests that it may influence genes and pathways involved in GABAergic signalling, but it is not established as a conventional direct GABA-A receptor drug.

Is Selank a benzodiazepine?

No. It is chemically and pharmacologically distinct from benzodiazepines.

Does Selank reduce anxiety?

Small clinical studies have reported reductions in anxiety symptoms, but the evidence remains limited and requires larger independent replication.

Is Selank approved for anxiety in the UK?

No.

Does Selank cause sedation?

It has often been described as less sedating than benzodiazepines, but individual effects and comprehensive safety have not been fully established.

Can Selank improve memory?

Some animal studies have reported improved learning performance. Strong evidence in healthy humans is lacking.

Can Selank improve focus?

It has not been established as an approved treatment for impaired attention or ADHD.

Does Selank increase BDNF?

Preclinical work suggests possible effects on neurotrophic pathways, but clinically meaningful human benefits have not been established.

Is Selank neuroprotective?

Neuroprotective effects have been proposed largely from preclinical research. Prevention of human neurological disease has not been demonstrated.

Does Selank improve sleep?

It is not an approved sleep treatment. Any benefit may be secondary to reduced anxiety, but robust evidence is lacking.

Does Selank lower cortisol?

A predictable clinically validated cortisol-lowering effect has not been established.

Does Selank treat depression?

No high-quality evidence establishes Selank as a treatment for major depressive disorder.

Does Selank affect the immune system?

Small studies suggest it may influence cytokine signalling, but the clinical significance remains uncertain.

Is Selank anti-inflammatory?

It may influence immune pathways, but it is not an established treatment for inflammatory disease.

Does Selank treat pain?

Its relationship with enkephalin metabolism is scientifically interesting, but robust human analgesic evidence is lacking.

How is Selank researched?

Many studies have used intranasal administration.

Does intranasal Selank go directly to the brain?

Direct and predictable delivery to specific brain regions has not been conclusively established.

What is the half-life of Selank?

Reliable comprehensive human pharmacokinetic data are limited, so precise universal claims should be treated cautiously.

How quickly does Selank work?

Published studies do not establish a guaranteed onset time that applies to everyone.

How long do Selank’s effects last?

One small study reported anxiety effects lasting beyond the treatment period, but this requires independent confirmation.

Can Selank be combined with antidepressants?

Safety data are insufficient. Combining it with psychiatric medication should not be assumed to be risk-free.

Can Selank be combined with diazepam?

The combination has been studied experimentally, but this does not establish the safety of unsupervised use.

Is Selank addictive?

Benzodiazepine-like dependence has not been demonstrated, but dedicated long-term dependence and withdrawal studies are limited.

Does Selank cause withdrawal?

A defined withdrawal syndrome has not been established, but long-term controlled evidence is lacking.

Can Selank cause anxiety?

Individual reactions to compounds affecting nervous-system signalling may differ, and paradoxical effects cannot be excluded.

Can Selank cause headaches?

Headache is a plausible adverse effect, although comprehensive incidence data are unavailable.

Is Selank safe long term?

Long-term safety has not been adequately established.

Is Selank safe during pregnancy?

There is insufficient evidence to consider it established as safe during pregnancy or breastfeeding.

Is Selank suitable for children?

Adequate safety and effectiveness data in children are lacking.

Is Selank prohibited by WADA?

It is not specifically named on the 2026 Prohibited List, but athletes should obtain specialist guidance because broad prohibited categories may still apply.

Is Selank the same as Semax?

No. They are different peptides with different sequences and research histories.

Which has more anxiety research: Selank or Semax?

Selank has been developed more specifically around anxiolytic research, while Semax has been studied more extensively in relation to neuroprotection and cognition.

Can animal studies prove that Selank works in humans?

No. Animal studies help identify mechanisms and research possibilities, but controlled human trials are needed to establish clinical effectiveness.

Selank research in context

What the evidence suggests

Available studies suggest that Selank may influence:

• Anxiety-related behaviour

• GABA-associated gene expression

• Enkephalin metabolism

• Neurotransmitter signalling

• Brain functional connectivity

• Cytokine regulation

Small human studies provide an early signal of possible anxiolytic activity.

What remains uncertain

Researchers have not yet established:

• A single primary receptor

• Definitive human pharmacokinetics

• Long-term safety

• Long-term effectiveness

• Optimal clinical indications

• Comparative effectiveness against modern treatments

• Safety with common psychiatric medicines

• Whether cognitive effects extend to healthy adults

• Whether immune changes produce meaningful health outcomes

Why further research is necessary

Encouraging early results are most useful when they lead to:

• Larger randomised trials

• Independent replication

• Transparent study registration

• Standardised outcome measures

• Long-term follow-up

• Detailed adverse-event reporting

Without these steps, uncertainty remains high.

Key takeaways

Selank is a synthetic seven-amino-acid peptide derived from a tuftsin-related sequence.

It was developed primarily for research into anxiety and stress.

Small clinical studies have reported anxiolytic effects, but the overall evidence remains limited compared with established anxiety treatments.

Its proposed mechanisms may involve:

• GABA-related signalling

• Enkephalin metabolism

• Gene expression

• Brain connectivity

• Immune regulation

No single primary Selank receptor has been conclusively identified.

Animal studies suggest possible cognitive and stress-related effects, but these findings do not establish improved cognition in healthy humans.

Selank is not an authorised UK medicine.

Its long-term safety, medicine interactions and effects in special populations remain insufficiently characterised.

Glossary

Anxiolytic: A substance that reduces anxiety.

Blood-brain barrier: A protective cellular barrier controlling which substances enter the brain from the bloodstream.

BDNF: Brain-derived neurotrophic factor, a protein involved in neuronal survival and plasticity.

Benzodiazepine: A class of medicines that enhance GABA-A receptor signalling.

Cytokine: A protein used by immune cells to communicate.

Enkephalin: A naturally occurring opioid peptide involved in pain, stress and emotional regulation.

Enkephalinase: An enzyme that breaks down enkephalins.

GABA: Gamma-aminobutyric acid, the main inhibitory neurotransmitter in the brain.

GABA-A receptor: An ion-channel receptor activated by GABA and influenced by benzodiazepines.

Gene expression: The process through which information in a gene is used to produce RNA or protein.

Heptapeptide: A peptide containing seven amino acids.

Immunomodulator: A substance that changes immune-system activity.

Intranasal: Administered through the nose.

Neuropeptide: A peptide involved in nervous-system signalling.

Nootropic: A broad term for a substance claimed to influence cognitive function.

Pharmacokinetics: The study of how a substance is absorbed, distributed, metabolised and eliminated.

Tuftsin: A naturally occurring immune-associated tetrapeptide derived from immunoglobulin G.

Important notice

This article is provided for educational purposes only.

It is not intended to diagnose, treat or prevent any disease or to replace advice from a qualified healthcare professional.

Selank is not an authorised medicine in the United Kingdom. Although preliminary studies have investigated its effects on anxiety, cognition, neurotransmission and immune signalling, the evidence remains limited and many online claims extend beyond what has been established in robust human clinical research.